# Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

> **NCT01813253** · PHASE3 · TERMINATED · sponsor: **Kuhnil Pharmaceutical Co., Ltd.** · enrollment: 400 (actual)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Cancer

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Nimotuzumab

## Key facts

- **NCT ID:** NCT01813253
- **Lead sponsor:** Kuhnil Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05-13
- **Primary completion:** 2018-02-19
- **Final completion:** 2018-02-19
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2018-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01813253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01813253, "Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01813253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*